A No-Code Cloud Platform for Life Science Research

In efforts to improve health, the life sciences industry faces several challenges – it must be able to unravel biological complexity, accelerate discoveries and ensure the reproducibility of experiments. Synthace recently announced the launch of its “Life Sciences R&D Cloud”. The platform is designed to improve and accelerate decision-making, helping scientists to overcome barriers to innovation.

Technology Networks spoke to Guy Levy-Yurista, CEO of Synthace to find out how the new cloud-based solution can support life science research.

Kate Robinson (KR): What inspired the production of the no-code cloud platform?

Guy Levy-Yurista (GLY): We are motivated to help life scientists achieve their goals and accelerate new therapeutics and other biological products to market faster. The no-code software platform was designed to address the barriers to innovation that so many scientists currently face. Our life sciences industry is under tremendous pressure to overcome biological complexity, accelerate speed to scientific insight and ensure the reproducibility of experiments. Scientists are also hindered by a lack of access to modern technologies that can satisfactorily handle the biological complexity they face on a daily basis. They need a platform to seamlessly automate experimentation and insight sharing in a unified global R&D environment. We want to do our part to enable scientists to deliver solutions more quickly to those who need them.

KR: How does your technology meet complexity, speed and data reproducibility demands?

GLY: We know that in the life sciences today, there are still widespread limitations on the study of increasingly complex biology, and global R&D teams need more effective ways to capture and communicate scientific insights. We need to equip scientists with the best technology (including both automation and software) to support rapid, confident decision-making. We believe that scientists should also be able to design and automate statistically powerful experiments to yield clear scientific insights that can be readily shared. The Synthace Life Sciences R&D Cloud enables every scientist to generate the highest quality data from robust, automated experiments, allowing better decision making and deeper and faster insights.

KR: How does the no-code platform differ from other platforms?

GLY: Our key differentiator lies in the fact that users of the Synthace Life Sciences R&D Cloud are given complete control over the entire “experiment lifecycle” – from experimental design, planning and automated execution, all the way through to data structuring, visualization and sharing. No coding experience is required, which makes it possible for a biologist to choose automation for any experimental activity. These capabilities further empower scientists to perform richer, higher value experiments, such as Design of Experiments (DOE), that would otherwise be impossible with any other product in the market. With Synthace, Quality by Design (QbD) becomes easy to implement as a routine and widespread approach to improve R&D outcomes.

KR: What avenues of research can your platform be used for?

GLY: Our platform is suited for any researcher who wants to improve their experimentation capabilities and accelerate development timelines. We’ve seen our software platform used by top global pharmaceuticals, high-growth biotech companies, leading contract development and manufacturing organizations and innovators in artificial intelligence, and they have achieved incredible leaps in the quality of science that they can do. Our customers use Synthace to tackle more complex scientific problems, easily automating a wide range of experiments to generate biological data at a volume that allows machine learning algorithms to rapidly improve. We see a future where the Synthace Life Sciences R&D Cloud enables every scientist to consistently generate the highest quality data from robust, automated experiments, and allows them to do so from anywhere they want.

KR: Do you envision that life science research will change, if so, how?

GLY: Absolutely. This decade is going to be the decade of biotechnology, genetics, genomics and all the adjacent areas. And the digitalization of life sciences is already in progress with more adoption of cloud-based platforms, as well as a general consensus amongst scientists that an open ecosystem of collaborative hardware and software providers will be the only way for our industry to keep evolving for the better. My goal is that when every new researcher joins a lab, they will receive a chair, a desk, a laptop and access to the Synthace Life Sciences R&D Cloud platform in order to design, execute and share their research to help drive scientific progress. Synthace will become the major force of innovation for all of life sciences R&D and manufacturing. In turn, life sciences will progress significantly for the benefit of all. It's about making significant breakthroughs more consistently, so that new kinds of vaccines and drugs can be delivered in record time to eliminate disease and help all of humanity. The technology is here, the transformation is underway. The best is yet to come!

Guy Levy-Yurista was speaking with Kate Robinson, Editorial Assistant for Technology Networks